Phase II Study Evaluating Docetaxel and CDDP as Neoadjuvant Chemotherapy Prior to Surgery, Followed by Adjuvant Docetaxel Plus CDDP in Chemonaive Patients With NSCLC Stage III
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
overall response rate
every cycle during 2nd-6th cycles
No
Chong-Jen Yu, M.D,Ph.D.
Principal Investigator
Department of Internal Medicine, National Taiwan University hospital
Taiwan: Department of Health
930911
NCT00172380
February 2005
March 2010
Name | Location |
---|